Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Submitted by
admin
on November 23, 2013 - 12:06pm
Source:
Yahoo/PR NewsWire
News Tags:
Nexavar
Bayer
ONYX Pharmaceuticals
Amgen
thyroid cancer
refractory differential thyroid cancer
Headline:
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Do Not Allow Advertisers to Use My Personal information
